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Purpose: To investigate the anti-inflammatory effects of aqueous extract of Orixa japonica (AEOJ) in 
lipopolysaccharide (LPS)-stimulated RAW 264.7 cells. 
Methods: The expression of mRNA and protein using RT-PCR and Western blot analysis was 
investigated. The level of nitric oxide (NO) production was analyzed using Griess reaction. Release of 
prostaglandin E2 (PGE2) and tumor necrosis factor-α (TNF-α) was determined using sandwich ELISA. 
Results: AEOJ potently inhibited the production of nitric oxide (NO), prostaglandin E2 (PGE2), and tumor 
necrosis factor-α (TNF-α) in LPS-stimulated RAW 264.7 cells. Consistent with these findings, AEOJ was 
also found to significantly reduce LPS-induced expression of inducible NO synthase (iNOS), 
cyclooxygenase-2 (COX-2), and TNF-α at the transcriptional level. Additionally, AEOJ attenuated LPS-
induced NF-κB activity via the inhibition of IκB phosphorylation and degradation. It was also found that 
the NF-κB inhibitor N-acetyl cysteine (NAC) attenuated LPS-induced gene expression of iNOS, COX-2, 
and TNF-α. These results indicate that AEOJ attenuates LPS-induced inflammatory mediators such as 
NO, PGE2, and TNF-α via suppression of NF-κB activity. 
Conclusion: These results suggest that AEOJ has a potential activity to alleviate LPS-induced 
inflammation. 
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INTRODUCTION 
 
Orixa japonica is a plant that is widely 
distributed in East Asia. Its aqueous extract 
AEOJ has been used traditionally for the 
treatment of cough, arthritis, dysentery, and 
malaria [1-3]. Sharma and his colleagues 
also reported that AEOJ is a good 
pharmaceutical candidate for the treatment of 
obesity caused by high fat-diet [4]. More 
recently, it was found that AEOJ significantly 
inhibits the growth of acne-inducing 
pathogenic bacteria, is not cytotoxic to the 
human cell line, and suppresses acne-
inducing inflammatory cytokines in THP-1 
cells [5]. However, little is known about the 




Inflammation is typified by the activation of 
immunocytes such as monocytes and 
macrophages, and the secretion of 
inflammatory mediators such as nitric oxide 
(NO), prostaglandin E2 (PGE2), and tumor 
necrosis factor-α (TNF-α). Although NO plays 
a significant role in host immune defense, 
vascular regulation, neurotransmission, and 
other systems under normal conditions, 
aberrant NO expression is thought to cause 
severe inflammatory disease [6,7]. 
Overproduction of inducible NO synthase 
(iNOS) is especially related to various human 
diseases such as inflammatory and neuronal 
disorders because of the upregulation of NO 
[8,9]. PGE2, which is derived from 
cyclooxygenase-2 (COX-2) by inflammatory 
stimulants, is also thought to be involved in 
the pathogenesis of some inflammatory 
diseases [10,11]. Additionally, TNF-α is highly 
expressed in macrophages involved in the 
inflammatory process and causes severe 
tissue damage, septic shock, atherosclerosis, 
and systemic inflammatory response 
syndrome [12,13]. Therefore, the inhibition of 
these inflammatory mediators would be an 
effective therapeutic approach for regulating 
LPS-induced septic shock. 
 
NF-κB is a nuclear transcription factor that 
regulates various genes related to immune 
and inflammatory responses, cell 
proliferation, growth, cell adhesion, and 
survival [14-15]. It is well known that NF-κB 
regulates the expression of inflammatory 
genes such as iNOS, COX-2, and TNF-α in 
order to boost inflammatory responses in 
early stages [16]. Previous studies also 
demonstrated that the inhibition of NF-κB 
activity may be useful for attenuating various 
inflammatory diseases including rheumatoid 
arthritis, septic shock and ischemia [17-19]. 
Therefore, effective inhibitors of NF-κB may 
explain its immunomodulatory and anti-
inflammatory effects in LPS-induced infla-
mmation. 
 
In the present study, an effort was made to 
show that AEOJ significantly inhibited the 
expression of iNOS, COX-2, and TNF-α, and 





Preparation of plant extract (AEOJ) 
 
O. Japonica was purchased from a local 
oriental herb store, Kwang Myoung Dang 
(Busan, Republic of Korea) in February 2005, 
and authenticated by Professor WS Ko, 
College of Oriental Medicine, Dongeui 
University, Busan, Republic of Korea. A 
voucher specimen was deposited at the 
Department of Oriental Medicine, Dongeui 
University. The plant material (100 g) was 
percolated with distilled water at 100 
0
C for 2 
h. The extract was filtered through 0.45 µm 
filter and the filtrate freeze-dried. The extract 
yield was approximately 4.1g and the extract 
(AEOJ) was kept at 4 
0
C until used. The 
extract was dissolved in phosphate buffered 
saline (PBS) at 1 mg/ml and filtered through 





diphenyl-tetrazolium bromide (MTT) were 
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purchased from Sigma Chemical Co. (St. 
Louis, MO, USA). Rabbit anti-human 
antibodies against iNOS, COX-2, p65, IκBα, 
and phospho (p)-IκBα were purchased from 
Santa Cruz Biotechnology (Santa Cruz, CA, 
USA). The antibody against β-actin was 
obtained from Sigma. Peroxidase-labeled 
goat anti-rabbit immunoglobulin was 
purchased from KOMA Biotechnology (Seoul, 
Republic of Korea). Dulbecco’s modified 
Eagle’s medium (DMEM) and fetal bovine 
serum (FBS) were obtained from WelGENE 
Inc. (Daegu, Republic of Korea). Other 
chemicals were purchased from Sigma. 
 
Cell Culture and viability 
 
RAW 264.7 murine macrophages cell line 
was kindly obtained from SJ Jeong (Kyung 
Hee University, Seoul, Republic of Korea) 
and cultured at 37 
0
C in 5 % CO2 in DMEM 
medium supplemented with 10 % FBS and 
antibiotics (WelGENE). For the analysis of 
cell viability, the cells were incubated with the 
indicated concentrations of AEOJ for 1 h prior 
to the treatment with LPS (1 µg/ml) for 24 h. 
Cell viability was determined by MTT assay. 
 
Isolation of total RNA and RT-PCR 
 
Total RNA was extracted from RAW 264.7 
cells using Trizol reagent (Invitrogen, 
Carlsbad, USA) according to the 
manufacturer’s instruction. One microgram of 
RNA was reverse-transcribed using MMLV 
reverse transcriptase (Bioneer, Daejeon, 
Republic of Korea). Then, cDNA was 
amplified by PCR using specific primer iNOS 
(forward 5’-cct cct cca ccc tac caa gt-3’ and 
reverse 5’-cac cca aag tgcttc agt ca-3’), COX-
2 (forward 5’-aag act tgc cag gct gaa ct-3’ 
and reverse 5’-ctt ctg cag tcc agg ttc aa-3’), 
TNF-α (forward 5’-gcg acg tgg aac tgg cag 
aa-3’ and reverse 5’-tcc atg ccg ttg gcc agg 
ag-3’) and β-actin (forward 5’-tgt gat ggt ggg 
aat ggg tca g-3’ and reverse 5’-ttt gat gtc acg 
cac gat ttc c-3’). The following PCR 
conditions were applied: COX-2 and iNOS, 
25 cycles of denaturation at 94 
0
C for 30 s, 
annealing at 59 
0
C for 30 s and extended at 
72 
0
C for 30 s; β-actin, 23 cycles of 
denaturation at 94 
0
C for 30 s, annealing at 
57 
0
C for 30 s and extended at 72 
0
C for 30 s. 
β-actin was used as an internal control to 
evaluate relative expression of COX-2, iNOS 
and TNF-α. 
 
Western blot analysis 
 
Total cell extracts were prepared using PRO-
PREP protein extraction solution (iNtRON 
Biotechnology, Sungnam, Republic of Korea). 
Cell lysates were centrifuged at 14,000 g at 4 
0
C for 10 min to obtain the supernatants. 
Supernatants were collected and protein 
concentrations determined using a Bio-Rad 
protein assay kit (Bio-Rad, Hercules, CA, 
USA). Samples were stored at -80°C or 
immediately used for Western blot analysis. 
The proteins were separated on SDS-
polyacrylamide gels and transferred to 
nitrocellulose membranes (Schleicher & 
Schuell, Keene, NH, USA). Proteins were 
detected using an enhanced chemilumi-
nescence detection system (Amersham, 




RAW 264.7 cells (2 × 10
5
 cells/ml) were 
plated onto 24-well plates and pretreated with 
the indicated concentrations of AEOJ for 1 h 
prior to stimulation with 1 µg/ml of LPS for 24 
h. Briefly, the sample supernatants were 
mixed with equal volume of Griess reagent 
(1% sulfanilamide in 5% phosphoric acid and 
0.1% naphthylethylenediamine dihydrochlo-
ride) and then incubated at room temperature 
for 10 min. The absorbance was measured at 
540 nm on a microplate reader (Thermo 
Electron Corporation, Marietta, OH, USA). 
Nitrite concentration was determined using a 
dilution of sodium nitrite as a standard. 
 
Measurement of TNF-α and PGE2 
 
The expression levels of TNF-α and PGE2 
were measured by enzyme-linked immuno-
sorbent assay (ELISA) kit (R&D Systems, 
Minneapolis, MN, USA) according to the 
manufacturer’s instructions. Briefly, RAW 
264.7 cells (2 × 10
5
 cells/ml) were plated in 
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24-well plates and pretreated with the 
indicated concentrations of AEOJ for 1 h prior 
to stimulation with 1 µg/ml of LPS for 24 h. 
One hundred microliters of culture-medium 
supernatants were collected for the 
determination of PGE2 and TNF-α 




All data were derived from at least three 
independent experiments. Statistical 
analyses were conducted using SigmaPlot 
software (version 6.0) Values were presented 
as mean ± SD. Significant differences 
between the groups were determined using 
the unpaired Student’s t-test. Statistical 




AEOJ is not cytotoxic to RAW 264.7 cells 
 
To assess the effects of AEOJ on the viability of 
RAW 264.7 cells, we treated cells with the 
indicated concentrations of AEOJ in the 
presence or absence of LPS for 24 h and 
analyzed cell viability by MTT assay. The 
viability of RAW 264.7 cells was not significantly 
altered by 24-h incubation with up to 2 mg/ml of 
AEOJ (Fig 1). Additionally, in the presence of 
LPS (1 µg/ml), AEOJ did not affect the viability 
of the cells. Therefore, in subsequent 
experiments, the concentration of AEOJ used 
was 2 mg/ml. 
 
AEOJ suppresses the expression of iNOS 
and NO 
 
To investigate whether AEOJ regulates NO 
production, cells were pretreated with AEOJ 
for 1 h before treatment with LPS for 24 h, 
and NO production was measured by 
performing the Griess reagent assay. NO 
production was reflected in the accumulation 
of nitrite in the cell culture medium. 
Treatment with LPS resulted in significant 
upregulation of nitrite production (17.3 ± 0.5 
µM), compared to the untreated control (6.2 ± 
0.4 µM; Fig 2A). However, RAW 264.7 cells 
pretreated with AEOJ displayed a marked 
decrease in the induction of nitrite (9.4 ± 0.3 
µM) after stimulation with LPS. Next, we 
investigated whether AEOJ regulates iNOS 
expression at the protein and gene levels. 
Consistent with the suppression of nitrite 
production, AEOJ induced dose-dependent 
downregulation of iNOS expression at the 
protein (Fig 2B) and gene levels (Fig 2C). 
These data indicate that AEOJ attenuates the 
upregulation of LPS-induced NO production 




Figure 1: Effect of AEOJ on the viability of RAW 264.7 
macrophage cells. Cells (2 × 10
5
 cells/ml) were 
incubated with the indicated concentrations of AEOJ for 
1 h before treatment with LPS (1.0 µg/ml) for 24 h. Cell 
viability was determined by MTT assay. Each value 
indicates the mean ± SD and is representative of results 
obtained from 3 independent experiments. 
 
AEOJ suppresses the expression of COX-2 
and PGE2 
 
To determine whether AEOJ suppresses the 
production of PGE2 in LPS-stimulated RAW 
264.7 cells, cells were stimulated with LPS and 
the amount of PGE2 secreted was measured 
using anti-PGE2-coated ELISA plates. RAW 
264.7 cells stimulated with LPS significantly 
increased the amount of PGE2 secreted (4826 ± 
123 pg/ml) as compared to untreated controls 
(145 ± 23 pg/ml; Fig 3A); however, this 
induction was markedly suppressed in AEOJ-
treated cells (1978 ± 98 pg/ml). Next, we 
confirmed the expression of COX-2 in RAW 
264.7 cells by Western blot analysis and RT-
PCR. Treatment with AEOJ decreased LPS-
induced COX-2 expression at the protein level 
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in a dose-dependent manner (Fig 3B). 
Additionally, RT-PCR data showed that the 
mRNA expression of COX-2 was increased by 
LPS treatment; however, pretreatment with 
AEOJ reversed LPS-induced COX-2 mRNA 
expression in RAW 264.7 cells. These data 
indicate that AEOJ suppresses the upregulation 
of LPS-stimulated PGE2 expression via the 





Figure 2: Effect of AEOJ on the inhibition of LPS-
induced NO and iNOS. (A) Cells (2 × 10
5
 cells/ml) were 
incubated with the indicated concentrations of AEOJ for 
1 h before treatment with LPS (1.0 µg/ml) for 24 h. (A) 
The amounts of NO were determined using the Griess 
reagent in the culture medium. *P < 0.01 is significantly 
different from the value in cells treated with LPS 
treatment alone. (B) In a parallel experiment, equal 
amounts of cell lysate were resolved on SDS-
polyacrylamide gels, transferred to nitrocellulose 
membranes, and probed with antibodies against iNOS. 
(C) Total RNA was isolated, and RT-PCR analyses of 
iNOS were performed. β-Actin was used as an internal 
control for Western blot analysis and RT-PCR. The 




Figure 3: Effect of AEOJ on the inhibition of LPS-
induced PGE2 and COX-2. (A) Cells (2 × 10
5
 cells/ml) 
were incubated with the indicated concentrations of 
AEOJ for 1 h before treatment with LPS (1.0 µg/ml) for 
24 h. (A) The amount of PGE2 was determined using a 
specific enzyme immunoassay performed according to 
the manufacturer’s instructions. *P < 0.01 is significantly 
different from the value in cells treated with LPS 
treatment alone. (B) In a parallel experiment, equal 
amounts of cell lysates were resolved on SDS-
polyacrylamide gels, transferred to nitrocellulose 
membranes, and probed with antibodies against COX-2. 
(C) Total RNA was isolated, and RT-PCR analyses of 
COX-2 were performed. β-Actin was used as an internal 
control for Western blot analysis and RT-PCR. The 
experiment was carried out in triplicate, and the mean 
was taken. 
 
AEOJ inhibits production of TNF- α at the 
gene level 
 
Next, we attempted to test the potential 
effects of AEOJ on the mRNA expression 
and secretion of TNF-α in LPS-stimulated 
RAW 264.7 cells. Cells were pretreated with 
2 mg/ml AEOJ for 1 h before treatment with 
LPS for 24 h. TNF-α production was 
assessed in the culture supernatant by 
ELISA. TNF-α was slightly expressed in 
untreated controls (1091 ± 78 pg/ml). 
However, LPS stimulation significantly 
increased TNF-α secretion at 24 h (4826 ± 
156 pg/ml; Fig 4A). Pretreatment with AEOJ 
significantly suppressed LPS-induced TNF-α 
secretion (2430 ± 57 pg/ml), even though 
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AEOJ itself did not alter the release of TNF-α 
in the absence of LPS. To evaluate whether 
the downregulation of AEOJ-induced TNF-α 
release was due to the regulation of the TNF-
α gene in LPS-stimulated RAW 264.7 cells, 
we performed RT-PCR analysis at 6 h after 
treatment with LPS. AEOJ reduced LPS-
induced expression of TNF-α mRNA in a 
dose-dependent manner (Fig 4B). These 
data indicate that AEOJ suppressed LPS-




Figure 4: Effect of AEOJ on LPS-induced TNF-α 
expression in RAW 264.7 cells. Cells (2 × 10
5
 cells/ml) 
were incubated with the indicated concentrations of 
AEOJ for 1 h before treatment with LPS (1.0 µg/ml) for 6 
h or 24 h. (A) After incubation for 24 h, the supernatant 
was collected, and the amount of TNF-α was measured 
by ELISA. (B) In a parallel experiment, the mRNA 
expression level of TNF-α was determined by RT-PCR 
analysis that was carried out 6 h after treatment with 
LPS. β-Actin was used as an internal control for RT-
PCR. The experiment was carried out in triplicate, and 
the mean was taken. 
 
AEOJ attenuates the expression of 
inflammatory mediator gene products via 
the suppression of NF-κB activity 
 
Because it is well known that NF-κB 
activation by LPS induces the expression of 
inflammatory mediators such as iNOS, COX-
2, and TNF-α, we performed Western blot 
analysis to investigate whether AEOJ 
regulates NF-κB activity. Because the 
translocation of NF-κB into the nucleus is 
preceded by the phosphorylation and 
degradation of the IκB protein, we analyzed 
the expression of IκB, p-IκB, and p65 in the 
cytosol. AEOJ inhibits LPS-induced 
degradation and phosphorylation of IκB (Fig 
5A). In addition, AEOJ helped sustain p65 
expression in the cytosol. In order to test 
whether NF-κB induces iNOS, COX-2, and 
TNF-α expression, we treated cells with a 
non-cytotoxic concentration of NAC, an NF-
κB inhibitor, and performed RT-PCR to check 
the expression of inflammatory mediator 
gene products. NAC significantly reversed 
LPS-induced iNOS, COX-2, and TNF-α 
expression at the transcriptional level (Fig 
5B). We confirmed that AEOJ was capable of 
attenuating LPS-induced inflammatory 




Figure 5: Effect of AEOJ on IκBα degradation, IκBα 
phosphorylation and p65 protein expression in LPS-
stimulated RAW 264.7 cells. (A) Cells were preincubated 
with AEOJ (2.0 mg/ml) for 1 h before stimulation with 
LPS (1.0 µg/ml) for 30 min. Cytoplasmic extracts were 
then prepared to determine the levels of IκBα, p-IκBα, 
and p65 by Western blot analysis. (B) In a parallel 
experiment, cells were pretreated with 5 mM NAC for 1h 
before treatment with LPS for 24 h. Total RNA was 
isolated, and RT-PCR was performed. β-Actin was used 
as an internal control for Western blot analysis and RT-
PCR. The experiment was carried out in triplicate, and 
the mean was taken. 
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DISCUSSION 
 
Although AEOJ has been used traditionally 
for the treatment of cough, arthritis, dysentery 
and malaria in Asia [1-3], little is known about 
the molecular mechanisms underlying its 
anti-inflammatory activities. In the present 
study, we showed that AEOJ remarkably 
attenuated the expression of inflammatory 
gene products such as iNOS, COX-2, and 
TNF-α at the protein and mRNA levels 
through the NF-κB pathway. 
 
It is well known that NO and PGE2 are the 
main macrophage-derived inflammatory 
mediators [20-21]. Furthermore, it has been 
reported that TNF-α is an inflammatory 
cytokine, which is considered as an 
endogenous mediator in LPS-induced shock 
[22]. Aberrant production of NO, PGE2, and 
TNF-α induces an inflammatory response 
that causes damage to neighboring cells and 
tissues of the host. Therefore, it has been 
thought a good strategy to reduce LPS-
induced inflammation through the 
suppression of these inflammatory mediators. 
Among the overproduced inflammatory 
mediators, NO has been strongly implicated 
in the pathogenesis of several disease 
processes such as septic shock, rheumatoid 
arthritis, and autoimmune diabetes [23]. 
Furthermore, PGE2 and TNF-α are highly 
detectable in the serum after induction by 
pro-inflammatory responses, which are 
implied in the pathogenesis of sepsis and 
inflammation [24,25]. According to the results 
of the present study, AEOJ suppressed the 
production of NO, PGE2, and TNF-α in LPS-
stimulated RAW 264.7 cells via the regulation 
of transcriptional expression. The mechanism 
by which AEOJ inhibits the expression of 
these gene products seems to involve the 
regulation of the common transcription factor. 
 
NF-κB is present in the cytoplasm as an 
inactivated dimer composed of p65 and p50 
subunits. In response to inflammatory stimuli, 
IκB is phosphorylated and degraded, and NF-
κB is released and translocated into the 
nucleus [26]. Because the expression of 
many inflammatory genes, including iNOS, 
COX-2, and TNF-α, are known to be 
modulated by the binding of NF-κB to its 
specific promoter regions [27], it is a good 
target for suppressing NF-κB activity for the 
regulation of LPS-induced inflammation. Our 
results showed that AEOJ decreases LPS-
induced phosphorylation of IκB and the 
resultant degradation of the IκB protein. It 
also helped sustain the expression of the p65 
protein in the cytoplasm. Pretreatment of 
cells with AEOJ suppressed this signal; this 
finding suggests that AEOJ inhibits NF-κB 
activation via inhibition of IκB 
phosphorylation. Taken together, these 
results suggest that AEOJ inhibits LPS-
induced NF-κB activity by suppressing the 
degradation and phosphorylation of IκB. 
However, we can-not rule out the possibility 
that the inflammatory response is attenuated 




This study confirmed that AEOJ has anti-
inflammatory effects, via the suppression of 
NF-κB activation in RAW 264.7 cells, thereby 
suppressing the release of NO, PGE2, and 
TNF-α. Therefore, understanding the 
mechanism of AEOJ action may lead to the 
development of more effective therapies for 
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